Miltefosine Acanthamoeba Keratitis

Acanthamoeba keratitis (AK) is a rare but potentially sight-threatening corneal infection caused by the free-living amoeba, Acanthamoeba. The condition mostly affects contact lens wearers, but it can also occur in individuals who have suffered a corneal injury or have a compromised immune system. The treatment of AK is challenging and can be prolonged. One drug that has shown promising results in the treatment of AK is Miltefosine.

Miltefosine is an oral medication that was originally developed as an antineoplastic agent. It is a lipophilic compound that can cross the blood-brain barrier and has broad-spectrum activity against different pathogens, including protozoa, bacteria, and fungi. It is thought to work by disrupting the cell membrane of the Acanthamoeba, leading to cell death.

Studies have shown that Miltefosine can be an effective treatment for AK. In a retrospective case series of 26 patients with AK, Miltefosine was used as a primary or adjunctive therapy. The study found that 23 of the 26 patients showed improvement in their symptoms and signs of infection within four weeks of treatment initiation. The drug was well-tolerated, with only a few patients reporting mild side effects such as gastrointestinal upset and skin rash.

Another study looked at the use of Miltefosine in combination with other treatments for AK. The study enrolled 40 patients who were treated with a combination of topical antiamoebic agents, oral Miltefosine, and topical steroids. The results showed that 38 of the 40 patients had complete resolution of the infection within three months of treatment initiation.

Miltefosine is not yet approved by the U.S. Food and Drug Administration (FDA) for the treatment of AK. However, it has been used off-label for this indication in several countries, including the United Kingdom, Germany, and India. In the United States, the drug can be obtained through the FDA’s compassionate use program.

Despite the promising results of Miltefosine in the treatment of AK, it is not without limitations. The drug is expensive and may not be readily available in some areas. It also has the potential for adverse effects, such as gastrointestinal upset, liver toxicity, and teratogenicity. Furthermore, Miltefosine may interact with other medications, such as warfarin and phenytoin.

In conclusion, Miltefosine is a promising treatment option for AK. It has shown to be effective and well-tolerated in several studies. However, its use should be carefully considered, and patients should be monitored closely for adverse effects. Future research is needed to determine the optimal dosing regimen and duration of therapy for AK.